Tempus AI, Inc. $TEM Shares Sold by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. reduced its stake in shares of Tempus AI, Inc. (NASDAQ:TEM) by 52.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 160,562 shares of the company’s stock after selling 177,679 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in Tempus AI were worth $12,972,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in shares of Tempus AI by 22.1% during the 3rd quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock worth $762,032,000 after acquiring an additional 1,706,837 shares in the last quarter. AQR Capital Management LLC purchased a new position in Tempus AI in the 2nd quarter valued at approximately $54,020,000. Geode Capital Management LLC raised its holdings in Tempus AI by 411.4% during the second quarter. Geode Capital Management LLC now owns 649,420 shares of the company’s stock worth $41,264,000 after purchasing an additional 522,443 shares during the last quarter. Legal & General Group Plc boosted its position in Tempus AI by 24.4% during the second quarter. Legal & General Group Plc now owns 450,645 shares of the company’s stock worth $28,634,000 after purchasing an additional 88,373 shares in the last quarter. Finally, Marex Group plc acquired a new stake in Tempus AI in the second quarter valued at $26,620,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus launched a pan‑cancer HRD‑RNA algorithm intended to improve tumor detection and HRD calling — the product release is being cited as a direct catalyst for recent upside in the stock. Tempus Shares Jump On AI Cancer Tool
• Positive Sentiment: Company is rolling out new AI tools across oncology, cardiology and mental health, signaling commercialization breadth beyond sequencing and bolstering the growth narrative that investors are rewarding. AI-Driven Innovation Accelerates Tempus AI’s Expansion Across MedTech
• Positive Sentiment: Mizuho initiated coverage with an “outperform” and a $100 price target, providing a high‑profile bullish endorsement that likely supported recent buying interest. Mizuho initiation coverage
• Neutral Sentiment: Research coverage by Robert W. Baird started, increasing institutional visibility; new coverage can boost liquidity but doesn’t guarantee directional moves absent model updates. Tempus AI Research Coverage Started at Robert W. Baird
• Neutral Sentiment: Market commentary pieces and a Benzinga options deep‑dive show elevated retail/derivative interest — signals of higher short‑term volatility and active positioning rather than fundamental change. Tempus AI Options Trading: A Deep Dive
• Neutral Sentiment: Analyst and media pieces (Zacks, Forbes) debate valuation and Q4 metrics — spotlighting that Tempus trades at a premium to traditional metrics and remains unprofitable on GAAP, which frames both upside expectation and valuation risk. Is TEM Stock A Buy At $60?
• Negative Sentiment: Despite product and coverage catalysts, fundamentals (negative GAAP profitability, elevated debt/equity) and technicals (current price below both 50‑ and 200‑day moving averages) increase downside risk if sentiment fades or earnings miss expectations. Unlocking Q4 Potential of Tempus

Tempus AI Price Performance

Tempus AI stock opened at $58.37 on Friday. The stock has a market capitalization of $10.38 billion, a P/E ratio of -49.05 and a beta of 5.22. Tempus AI, Inc. has a 12-month low of $36.22 and a 12-month high of $104.32. The company has a debt-to-equity ratio of 2.45, a current ratio of 3.28 and a quick ratio of 3.12. The firm’s 50-day moving average is $62.35 and its two-hundred day moving average is $73.50.

Insider Activity

In other Tempus AI news, CEO Ryan Fukushima sold 9,592 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $59.05, for a total transaction of $566,407.60. Following the transaction, the chief executive officer owned 694,354 shares of the company’s stock, valued at $41,001,603.70. This represents a 1.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO James William Rogers sold 19,966 shares of the firm’s stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $73.20, for a total value of $1,461,511.20. Following the sale, the chief financial officer owned 111,250 shares in the company, valued at $8,143,500. This trade represents a 15.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 775,159 shares of company stock worth $50,789,800. 26.27% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on TEM shares. Morgan Stanley lifted their price target on Tempus AI from $80.00 to $85.00 and gave the stock an “overweight” rating in a research note on Monday, December 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Tempus AI in a report on Thursday, January 22nd. HC Wainwright reduced their price target on shares of Tempus AI from $98.00 to $89.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Needham & Company LLC increased their price target on shares of Tempus AI from $70.00 to $100.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Finally, Canaccord Genuity Group cut their price objective on Tempus AI from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Monday, December 22nd. Eight investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Tempus AI currently has a consensus rating of “Hold” and an average price target of $85.92.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.